Does TREAT give the boot to ESAs in the treatment of CKD anemia?

Journal of the American Society of Nephrology

Volumn 21, Issue 1, 2010, Pages 2-6

  Singh, Ajay K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMORBIDITY; EDITORIAL; HEALTH INSURANCE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOEMBOLISM;

EID: 75149198323     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009111127     Document Type: Editorial

References (20)

1. Dickens C: A Tale of Two Cities, London, Penguin Classics, 2003 [Originally published 1859, edited and with an introduction and notes by Richard Maxwell]
2. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, the TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med October 30, 2009 [epub ahead of print]
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
4. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
5. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84[Suppl 1]: 3-10, 2001
6. Egrie J, Grant JR, Gillies DK, Aoki KH, Strickland TW: The role of carbohydrate on the biological activity of erythropoietin. Glycoconj J 10: 263-269, 1993
7. Catlin DH, Breidbach A, Elliott S, Glaspy J: Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48: 2057-2059, 2002
8. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J: Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79-89, 1998
9. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK: A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int November 4, 2009 [epub ahead of print]
10. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J Am Soc Nephrol 16: 3403-3410, 2005
11. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004
12. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetinalpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
13. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG: Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 54: 498-510, 2009
14. Singh AK: Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: Pro. J Am Soc Nephrol 20: 1436-1441, 2009
15. Coyne DW: From anemia trials to clinical practice: Understanding the risks and benefits when setting goals for therapy. Semin Dial 21: 212-216, 2008
16. KDOQI, National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47[Suppl 3]: S16-S85, 2006
17. Courtney AE, Maxwell AP: Critiques of Clinical Guidelines in Nephrology: Anaemia. Nephron Clin Pract 110: c115-c125, 2008
18. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64: 295-304, 2003
19. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924, 2008
20. Dickens C: Hard Times, London, Penguin Books Ltd., 1995